1. Huang J, Lucero-Prisno III DE, Zhang L, Xu W, Wong SH, Siew C. Ng, et al. Updated epidemiology of gastrointestinal cancers in East Asia. Nat Rev Gastroenterol Hepatol. 2023;20(5):271-87. [ DOI:10.1038/s41575-022-00726-3] [ PMID] 2. Short MW, Burgers KG, Fry VTJAfp. Esophageal cancer. Am Fam Physician. 2017;95(1):22-8. 3. Uhlenhopp DJ, Then EO, Sunkara T, Gaduputi VJCjog. Epidemiology of esophageal cancer: update in global trends, etiology and risk factors. Clin J Gastroenterol. 2020;13(6):1010-21. [ DOI:10.1007/s12328-020-01237-x] [ PMID] 4. Islami F, Kamangar F, Nasrollahzadeh D, Møller H, Boffetta P, Malekzadeh RJEJoC. Oesophageal cancer in Golestan Province, a high-incidence area in northern Iran-a review. Eur J Cancer. 2009;45(18):3156-65. [ DOI:10.1016/j.ejca.2009.09.018] [ PMID] 5. Gholipour M, Islami F, Roshandel G, Khoshnia M, Badakhshan A, Moradi A, et al. Esophageal cancer in Golestan Province, Iran: a review of genetic susceptibility and environmental risk factors. Middle East J Dig Dis. 2016 ;8(4):249-266. [ DOI:10.15171/mejdd.2016.34] [ PMID] [ ] 6. Tarazi M, Chidambaram S, Markar SRJC. Risk factors of esophageal squamous cell carcinoma beyond alcohol and smoking. Cancers. 2021;13(5):1-13. [ DOI:10.3390/cancers13051009] [ PMID] [ ] 7. Lagares M, Silva K, Barbosa A, Rodrigues D, Costa I, Martins J, et al. Analysis of p53 gene polymorphism (codon 72) in symptomatic patients with atherosclerosis. Genet Mol Res. 2017;16(3): 1-9. [ DOI:10.4238/gmr16039721] [ PMID] 8. Sherr CJ, Bartek J. Cell Cycle-Targeted Cancer Therapies. Annu Rev Cancer Biol. 2017; 1 : 41-57. [ DOI:10.1146/annurev-cancerbio-040716-075628] 9. Pietsch E, Humbey O, Murphy M. Polymorphisms in the p53 pathway. Oncogene. 2006;25(11):1602-11. [ DOI:10.1038/sj.onc.1209367] [ PMID] 10. Shao Y, Tan W, Zhang S. P53 gene codon 72 polymorphism and risk of esophageal squamous cell carcinoma: a case/control study in a Chinese population. Dis Esophagus. 2008;21(2):139-43. [ DOI:10.1111/j.1442-2050.2007.00746.x] [ PMID] 11. Kafshdooz T, Tabrizi AD, Mohaddes Ardabili S, Kafshdooz L, Ghojazadeh M, Gharesouran J, et al. Polymorphism of p53 gene codon 72 in endometrial cancer: correlation with tumor grade and histological type. Asian Pac J Cancer Prev. 2014;15(22):9603-6. [ DOI:10.7314/APJCP.2014.15.22.9603] [ PMID] 12. Zhou Y, Li N, Zhuang W, Liu GJ, Wu TX, Yao X, et al. P53 codon 72 polymorphism and gastric cancer: A meta‐analysis of the literature. Int J Cancer. 2007;121(7):1481-6. [ DOI:10.1002/ijc.22833] [ PMID] 13. Chen X, Zhang T, Su W, Dou Z, Zhao D, Jin X, et al. Mutant p53 in cancer: from molecular mechanism to therapeutic modulation. Cell Death Dis. 2022;13(11):974. [ DOI:10.1038/s41419-022-05408-1] [ PMID] [ ] 14. Kampouraki E, Lourou M, Zervou MI, Ampazoglou E-D, Yachnakis E, Katzilakis N, et al. Role of CXCL12, TP53 and CYP1A1 gene polymorphisms in susceptibility to pediatric acute lymphoblastic leukemia. Oncology Letters. 2021; 22(3): 1-8. [ DOI:10.3892/ol.2021.12920] [ PMID] [ ] 15. Koushik A, Platt RW, Franco ELJCEB, Prevention. p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review. Cancer Epidemiol Biomarkers Prev. 2004;13(1):11-22. [ DOI:10.1158/1055-9965.EPI-083-3] [ PMID] 16. Sul J, Yu G-P, Lu Q-Y, Lu M-L, Setiawan VW, Wang M-R, et al. P53 Codon 72 polymorphisms: a case-control study of gastric cancer and potential interactions. Cancer Letters. 2006;238(2):210-23. [ DOI:10.1016/j.canlet.2005.07.004] [ PMID] [ ] 17. Jin X, Wu X, Roth JA, Amos CI, King TM, Branch C, et al. Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis. 1995;16(9):2205-8. [ DOI:10.1093/carcin/16.9.2205] [ PMID] 18. Granja F, Morari J, Morari EC, Correa LA, Assumpcao LgV, Ward LSJCl. Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer. Cancer letters. 2004;210(2):151-7. [ DOI:10.1016/j.canlet.2004.01.016] [ PMID] 19. Homady MH, Salih TS, Al-Jubori MM, Younus MD. Immunohistochemical and molecular studies of p53 and KRAS protein and their relations to colorectal carcinoma. Cihan Univ-Erbil Scient J. 2021;5(1):28-33. [ DOI:10.24086/cuesj.v5n1y2021.pp28-33] 20. Katkoori V, Goli R, Jia X, Callens T, Messiaen L, Jhala N, et al. Prognostic value of molecular alterations in high grade colorectal adenocarcinomas varies in African-Americans and Caucasians. Cancer Res. 2007;67(9):141. 21. Hoyos D, Greenbaum B, Levine AJ. The genotypes and phenotypes of missense mutations in the proline domain of the p53 protein. Cell Death Differ. 2022;29(5):938-45. [ DOI:10.1038/s41418-022-00980-7] [ PMID] [ ] |
.png)
.png){kind=small}
